TrialCancer science2018

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.

Masafumi Ikeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.